Trial Profile
A Phase I Dose-Escalation Safety and Tolerability Study of MirvetuximabSoravtansine (IMGN853) and Gemcitabine in Patients With FRa-positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial Cancer, or Triple Negative Breast Cancer (TNBC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 26 Feb 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Mirvetuximab soravtansine (Primary)
- Indications Endometrial cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer; Triple negative breast cancer; Uterine cancer
- Focus Adverse reactions
- 20 Feb 2024 Status changed from active, no longer recruiting to completed.
- 07 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 17 Feb 2022 Planned End Date changed from 22 Feb 2023 to 22 Nov 2023.